Study on Pembrolizumab/Quavonlimab in MSI-H/dMMR Stage IV Colorectal Cancer
A clinical trial is evaluating the efficacy and safety of co-formulated pembrolizumab/quavonlimab in patients with MSI-H or dMMR Stage IV colorectal cancer.
Therapeutic Area
Therapeutic area intelligence for Combination Immunotherapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.